Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett King

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Journal of Allergy and Clinical Immunology|December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkersEmma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Journal of the American Academy of Dermatology|August 12, 2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case seriesVivian Y Shi, Khiem Tran, Forum Patel, et al.
Pharmacology Research & Perspectives|July 5, 2024
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areataSamira Anderson, Guido Cavaletti, Linda J Hood, et al.
Journal of the American Academy of Dermatology|November 12, 2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trialKhaled Ezzedine, Elena Peeva, Yuji Yamaguchi, et al.
Nature Communications|June 6, 2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosisWilliam Damsky, Alice Wang, Daniel J Kim, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
Journal of the American Academy of Dermatology|March 14, 2020
The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areataNekma Meah, Dmitri Wall, Katherine York, et al.
Journal of the American Academy of Dermatology|September 14, 2020
The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areataNekma Meah, Dmitri Wall, Katherine York, et al.
JAMA Dermatology|March 3, 2021
A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)Dmitri Wall, Nekma Meah, Katherine York, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 23, 2025
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024Nekma Meah, Jane Li, Dmitri Wall, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Journal of Allergy and Clinical Immunology|December 5, 2021
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkersEmma Guttman-Yassky, Ana B Pavel, Aisleen Diaz, et al.
Journal of the American Academy of Dermatology|August 12, 2015
100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case seriesVivian Y Shi, Khiem Tran, Forum Patel, et al.
Pharmacology Research & Perspectives|July 5, 2024
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areataSamira Anderson, Guido Cavaletti, Linda J Hood, et al.
Journal of the American Academy of Dermatology|November 12, 2022
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trialKhaled Ezzedine, Elena Peeva, Yuji Yamaguchi, et al.
Nature Communications|June 6, 2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosisWilliam Damsky, Alice Wang, Daniel J Kim, et al.
Journal of the American Academy of Dermatology|April 29, 2020
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitisEric Simpson, Robert Bissonnette, Lawrence F Eichenfield, et al.
Journal of the American Academy of Dermatology|March 14, 2020
The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areataNekma Meah, Dmitri Wall, Katherine York, et al.
Journal of the American Academy of Dermatology|September 14, 2020
The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areataNekma Meah, Dmitri Wall, Katherine York, et al.
JAMA Dermatology|March 3, 2021
A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)Dmitri Wall, Nekma Meah, Katherine York, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 23, 2025
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024Nekma Meah, Jane Li, Dmitri Wall, et al.
Pageof 8